22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Fudan University unveils archaeology project to explore Silk Road heritage
- Chinese vice-premier urges all-out efforts to tackle Chikungunya fever outbreak
- China's ocean economy buckles pressure and posts 5.8% rise in marine GDP
- China's Qin Haiyang wins men's 200m breaststroke gold at World Aquatics Championships
- Across China: 80 years on, US youth carry the Flying Tigers' torch
- Shanghai's intl business zone offers visa-free entry to invited individuals
